Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
The metabolic syndrome is a constellation of epidemics, involving type 2 diabetes mellitus (T2DM), hypertension, hyperlipidemia, and obesity, that share common biological and societal pathways.[1 –4] This pathological metabolic milieu collectively increases the individual’s risk of cardiovascular diseases, including coronary heart disease and heart failure.[3,5,6] More recently, metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasingly recognized as a key man ifestation of this systemic metabolic disease.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Nicholas W.S. Chew, Xin Hui Pan, Bryan Chong, Chanchal Chandramouli, Mark Muthiah, Carolyn S.P. Lam Source Type: research
More News: Cardiology | Cardiovascular | Coronary Heart Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Heart | Heart Disease | Heart Failure | Hypertension | Liver | Liver Disease | Metabolic Syndrome | Obesity | Urology & Nephrology